Consensus statement on immune modulation in multiple sclerosis and related disorders during the covid-19 pandemic: Expert group on behalf of the indian academy of neurology
Rohit Bhatia, M.V. Padma Srivastava, Dheeraj Khurana, Lekha Pandit, Thomas Mathew, Salil Gupta, M Netravathi, Sruthi S Nair, Gagandeep Singh, BhimS Singhal
Abstract
Knowledge related to SARS-CoV-2 or 2019 novel coronavirus (2019-nCoV) is still emerging and rapidly evolving. We know little about the effects of this novel coronavirus on various body systems and its behaviour among patients with underlying neurological conditions, especially those on immunomodulatory medications. The aim of the present consensus expert opinion document is to appraise the potential concerns when managing our patients with underlying CNS autoimmune demyelinating disorders during the current COVID-19 pandemic.
Topics & Concepts
PandemicMedicineMultiple sclerosisCoronavirus disease 2019 (COVID-19)NeurologyCoronavirusStatement (logic)2019-20 coronavirus outbreakExpert opinionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BetacoronavirusImmune modulationDemyelinating DisorderFamily medicineImmune systemIntensive care medicineImmunologyPsychiatryVirologyPathologyLawDiseasePolitical scienceOutbreakInfectious disease (medical specialty)Multiple Sclerosis Research StudiesLong-Term Effects of COVID-19Peripheral Neuropathies and Disorders